Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicentric, Randomized, Double-blind, Parallel, Placebo-controlled Phase III Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

Next Previous
Trial Profile

A Multicentric, Randomized, Double-blind, Parallel, Placebo-controlled Phase III Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Sep 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sovateltide (Primary)
  • Indications Ischaemic stroke
  • Focus Registrational; Therapeutic Use
  • Acronyms RESPECT-ETB
  • Sponsors Pharmazz

Most Recent Events

  • 15 Sep 2026 Planned End Date changed from 1 Nov 2026 to 1 Dec 2027.
  • 15 Sep 2026 Planned primary completion date changed from 1 Sep 2026 to 1 Sep 2027.
  • 14 Sep 2026 According to a Pharmazz media release, this trial will be presented at the 18th World Stroke Congress, taking place 21-23 October 2026, at the Convention & Exhibition Center, Seoul, South Korea.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top